230,161 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 230,161 shares of the company’s stock, valued at approximately $522,000. Renaissance Technologies LLC owned approximately 0.47% of Cabaletta Bio at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Cabaletta Bio by 48.2% during the third quarter. Barclays PLC now owns 61,130 shares of the company’s stock worth $288,000 after purchasing an additional 19,891 shares during the period. Geode Capital Management LLC lifted its position in Cabaletta Bio by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,644 shares of the company’s stock worth $5,168,000 after buying an additional 124,071 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Cabaletta Bio during the 4th quarter valued at $40,000. SG Americas Securities LLC grew its holdings in shares of Cabaletta Bio by 23.3% during the 4th quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock valued at $98,000 after acquiring an additional 8,161 shares in the last quarter. Finally, HealthInvest Partners AB increased its stake in shares of Cabaletta Bio by 46.8% in the fourth quarter. HealthInvest Partners AB now owns 247,454 shares of the company’s stock worth $554,000 after acquiring an additional 78,932 shares during the last quarter.

Wall Street Analysts Forecast Growth

CABA has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating and issued a $23.00 target price on shares of Cabaletta Bio in a research note on Tuesday, April 1st. Wells Fargo & Company lowered their price target on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 1st. UBS Group dropped their price objective on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Morgan Stanley reduced their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Tuesday, April 1st. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $21.00.

Cabaletta Bio Stock Up 7.2 %

NASDAQ:CABA opened at $1.34 on Friday. The company’s 50 day moving average is $1.45 and its 200-day moving average is $2.41. Cabaletta Bio, Inc. has a 12 month low of $0.99 and a 12 month high of $13.50. The firm has a market cap of $68.00 million, a price-to-earnings ratio of -0.62 and a beta of 2.44.

Cabaletta Bio (NASDAQ:CABA) last released its earnings results on Monday, March 31st. The company reported ($0.65) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.65). Research analysts predict that Cabaletta Bio, Inc. will post -2.34 EPS for the current fiscal year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.